Regeneron Pharmaceuticals (REGN)

• Market cap: $60.7B
• 1 day: 2.67%
• 5 days: -1.95%
• 1 month: 0%
• 3 months: 0.35%
• 6 months: 0.27%
• Year to date: -19.94%
• 1 year: -43.54%
• 5 years: -4.7%
• 10 years: 12.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,207